2004 Volume 21 Issue 2 Pages 131-137
We obtained a total of 397 isolates ofCampylobacterspp. (352 of C. jejuni, 16 of C. coli, and 29 ofC. fetus) from humans, poultry, cattle, and pigs, and examined the susceptibilities of these isolates to 8 antimicrobics, ampicillin (ABPC), gentamicin (GM), erythromycin (EM), imipenem (IPM), tetracycline (TC), chloramphenicol (CP), nalidixic acid (NA), and ciprofloxacin (CPFX). The results obtained were summarized as follows: (i) allCampylobacterisolates were susceptible to IPM; (ii) almost all isolates except for only a few C.jejuniisolates were susceptibleto GM and CP; (iii) 27.6 to 75.0% of the isolates in threeCampylobacterspecies were resistant to TC; (iv) 30.1 to 100% and 27.6 to 62.5% of the isolates in these species were resistant to NA and CPFX, respectively, and the cross-resistance to these two antimicrobics was also recognized in most isolates ofC. jejuniandC. coli.In C. jejuni, 46.2% and 44.6% of human isolates were resistant to NA and CPFX, respectively (high frequency), but 27.8% (NA) and 26.1% (CPFX) of poultry isolates, and 19.0% (NA) and 16.7% (CPFX) of cattle isolates were resistant (low frequency); (v) 43.8% of C. coli isolates were resistant to EM (high frequency), but only 5.4% of C.jejuniisolates and 3.4% of C.fetusisolates were resistant (very low frequency); and (vi) allC. jejuniisolates from cattle were susceptible to ABPC, whereas approximately 20% of theC. jejuniisolates from humans and poultry were resistant. These findings suggest thatC. jejuniresistant to fluoroquinolones gradually expands, but EM is still effective and available for treatment of human infection byC. jejuni.
